FDA
-
-
-
-
-
-
-
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
-
-
-
-
-
-
-
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
-
-
-
-
-
-
-
Myriad Genetics Adds Folate Receptor Alpha to Precise⢠Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
-
-
-
-
-
-
-
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
-
-
-
-
-
-
-
Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise⢠Oncology Solutions
-
-
-
-
-
-
-
Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
-
-
-
-
-
-
-
Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

